Esperion released some positive top-line data this afternoon on their last Phase 3 LDL-C lowering trial (Study 2). This 52-week trial is much cleaner safety-wise than the previous one announced earlier this year. Plus, some pretty good MACE numbers (though MACE was not a primary endpoint of Study 2). Their official CVOT is still ongoing through 2022.

3-component MACE: 2.7 percent for bempedoic acid compared to 4.7 percent for placebo

4-component MACE: 5.7 percent for bempedoic acid compared to 7.8 percent for placebo

5-component MACE: 6.1 percent for bempedoic acid compared to 8.2 percent for placebo

Looks like they are now done with their Phase 3 LDL-C lowering program and are still on track for NDA submission for LDL-C lowering early next year. Still a lot of haters out there not thinking that there is much room for bempedoic acid in this crowded LDL-C lowering field. Especially in light of the lowered prices of the PCSK9 drugs. The field is hungry for other mechanisms to lower cardiovascular risk other than LDL-C (bempedoic acid also lowers hsCRP). 

C'mon apabetalone. Get 'er done.